Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2–Low
A quarter of high-risk, metastatic, or recurrent EC exhibited HER2 overexpression. The presence of HER2 overexpression in all clinical and molecular categories highlights the need for broad testing and offers treatment options for a wide range of patients.
Authors
- Anneke M. Westermann (ORCID: https://orcid.org/0000-0002-5588-7441)
- D. van Dijk (ORCID: https://orcid.org/0009-0008-5129-4631)
- Judith R. Kroep (ORCID: https://orcid.org/0000-0003-2671-1903)
- Alicia León‐Castillo (ORCID: https://orcid.org/0000-0003-0873-5362)
- Tjalling Bosse (ORCID: https://orcid.org/0000-0002-6881-8437)
- Alexandra Léary (ORCID: https://orcid.org/0000-0002-2043-2244)
- Cor D. de Kroon (ORCID: https://orcid.org/0000-0002-7999-4161)
- Cathalijne Post (ORCID: https://orcid.org/0000-0003-2534-6887)
- Stephanie M. de Boer (ORCID: https://orcid.org/0000-0002-8454-1597)
- Ina M. Jürgenliemk‐Schulz (ORCID: https://orcid.org/0000-0003-4911-006X)
- David Bowes (ORCID: https://orcid.org/0000-0002-9932-7067)
- Catherine Genestie (ORCID: https://orcid.org/0000-0003-0927-1985)
- Lisa Vermij (ORCID: https://orcid.org/0000-0003-4687-5550)
- Linda Mileshkin (ORCID: https://orcid.org/0000-0001-6826-6014)
- Linda S. Nooij (ORCID: https://orcid.org/0000-0001-5741-4595)
- Carien L. Creutzberg (ORCID: https://orcid.org/0000-0002-7008-4321)
- Nanda Horeweg (ORCID: https://orcid.org/0000-0002-8581-4753)
- Melanie Powell (ORCID: https://orcid.org/0000-0002-9850-8181)
- Jan J. Jobsen (ORCID: https://orcid.org/0000-0001-7663-0170)
- Vincent T.H.B.M. Smit (ORCID: https://orcid.org/0000-0003-3730-5652)
Institutions
- Dalhousie University (CA)
- Barts Health NHS Trust (GB)
- Leiden University Medical Center (NL)
- Peter MacCallum Cancer Centre (AU)
- Medisch Spectrum Twente (NL)
- Institut Gustave Roussy (FR)
- University Medical Center Utrecht (NL)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1200/jco.23.02768
- Citations
- 11
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 3.11